Tag Archives: Sunshine Act

Open Payments: A New Dawn for Transparency

The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realised. Michael Christel reports.
Posted in compliance, Events, FDA, Meetings, Regulatory | Also tagged , , , , | Leave a comment

Confessions of a Compliance Director

In anticipation of CBI’s (a PharmExec sibling company) 11th Annual Pharma Compliance Congress happening later this month, PharmExec spoke with a compliance director at a mid-sized pharma ($5 billion in annual sales) about life under a CIA, and the potential trigger issues for 2014. In an effort to promote candor and avoid overly circumspect responses, […]
Posted in compliance, Corporate Responsibility, E-Media, Emerging Markets, FDA, healthcare, Legal, Marketing, Medical Education, pricing, Regulatory, Sales, social media, Strategy | Also tagged , , , , , , , , , , , , , | Leave a comment

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , | Leave a comment

Pharma's Transparency Troubles

Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler It seems like open season on the pharmaceutical industry. Academics and consumer activists charge pharma companies with hiding clinical trial information on medical product safety, fueling […]
Posted in Europe, FDA, Guest Blog, Op-Ed, Regulatory | Also tagged , , , , | Leave a comment

Putting a Price Tag on Compliance: Cheap Change or Big Bucks?

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.  But relatively little scrutiny has been accorded to another pressing question:  how much will all this new reporting cost?  The burden of compliance for not just this new law but in many […]
Posted in compliance, Marketing, Regulatory, Strategy | Also tagged , , , , | 1 Comment
  • Categories

  • Meta